Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Quality of life (QoL) in patients with recurrent ovarian clear cell carcinoma (rOCCC) receiving durvalumab (D) versus physician's choice chemotherapy (PCC) in the randomized phase II MOCCA/APGOT-OV2/GCGS-OV3 trial.
- Authors
- Ngoi, NYL[Ngoi, Natalie Y. L.]; Sun, HY[Sun, Haoyang]; Choi, CH[Choi, Chel Hun]; Heong, V[Heong, Valerie]; Ow, SGW[Ow, Samuel Guan Wei]; Chay, WY[Chay, Wen Yee]; Kim, HS[Kim, Hee Seung]; Goss, G[Goss, Geraldine]; Goh, JC[Goh, Jeffrey C.]; Lin, MQ[Lin, Meiqi]; Lim, D[Lim, Diana]; Kim, JW[Kim, Jae-Weon]; Friedlander, M[Friedlander, Michael]; Tai, BC[Tai, Bee Choo]; Kim, K[Kim, Kidong]; Tan, DSP[Tan, David Shao Peng]
- Issue Date
- 1-Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.